Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023719 | 1.00 | GCK (0.41) | GCKIDO1CFDKCNH2IDH2 | |
| SCHEMBL2021063 | 0.92 | GCK (0.41) | GCKKCNH2AKR1C3EPHX2 | |
| SCHEMBL2021061 | 0.92 | GCK (0.41) | GCKKCNH2AKR1C3EPHX2 | |
| SCHEMBL2018441 | 0.90 | GCK (0.45) | GCKKCNH2IDH2AKR1C3EPHX2 | |
| SCHEMBL2018439 | 0.90 | GCK (0.45) | GCKKCNH2IDH2AKR1C3EPHX2 | |
| SCHEMBL2016674 | 0.88 | GCK (0.42) | GCKKCNH2AKR1C3EPHX2 | |
| SCHEMBL2016671 | 0.88 | GCK (0.42) | GCKKCNH2AKR1C3EPHX2 | |
| SCHEMBL2021506 | 0.88 | GCK (0.42) | GCKKCNH2IDH2AKR1C3EPHX2 | |
| SCHEMBL2021503 | 0.88 | GCK (0.42) | GCKKCNH2IDH2AKR1C3EPHX2 | |
| SCHEMBL2020801 | 0.85 | GCK (0.40) | GCKKCNH2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275414-B1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2015-06-10 | — | — | EP | claimed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | claimed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | GCK 188/4885IDO1 2725/4885CFD 3743/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | GCK 188/4885IDO1 2725/4885CFD 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.